

COPD Inhaled Medication Table Update

This is a 2020 Update to the BC Provincial Academic Detailing (PAD) Service's 2017 Table "Inhaled medications for COPD & Asthma" which includes some additions to the inhaled medications list and COPD BC PharmaCare coverage changes. For complete details on the stepwise approach to PharmaCare coverage of COPD inhalers in British Columbia please see the PharmaCare COPD website.

COPD: Inhaled Medications	Marketed in Canada ¹⁻²			
Medication	Brand Name, <i>Inhaler Device</i> Dose per Inhalation	Usual Adult Dose	Cost 30 days	BC PharmaCare Coverage
SABA Short Acting Beta ₂ Agonis	st			
salbutamol	Ventolin HFA <i>MDI</i> , Airomir <i>MDI</i> , generics (100 mcg)	1-2 inh QID (max 8 inh/day)	\$6 /200 inh	regular benefit
	Ventolin <i>Diskus</i> (200 mcg)	1 inh every 4-6 hours (max 4 inh/day)	\$11 /60 inh	non-benefit
terbutaline	Bricanyl <i>Turbuhaler</i> (500 mcg)	1-2 inh PRN (max 6 inh/day)	\$9 /100 inh	regular benefit
SAMA Short Acting Muscarinic	Antagonist			
pratropium	Atrovent HFA MDI (20 mcg)	2-4 inh TID-QID (max 12 inh/day)	\$22 /200 inh	regular benefit
SAMA+SABA Short Acting Muse	carinic Antagonist + Short Acting Bet	a ₂ Agonist		
ipratropium + salbutamol	Combivent Respimat (20/100 mcg)	1 inh QID (max 6 inh/day)	\$32 /120 inh	regular benefit
LAMA Long Acting Muscarinic	Antagonist			
umeclidinium	Incruse Ellipta (62.5 mcg)	1 inh once a day	\$54	regular benefit
tiotropium	Spiriva Respimat (2.5 mcg)	2 inh once a day	\$59	
tiotropium	Spiriva <i>HandiHaler</i> (18 mcg)	1 inh once a day	\$59	limited coverage after a 1 month trial of each regular benefit LAM
aclidinium	Tudorza <i>Genuair</i> (400 mcg)	1 inh BID	\$57	
glycopyrronium	Seebri <i>Breezhaler</i> (50 mcg)	1 inh once a day	\$57	
LABA Long Acting Beta ₂ Agonis	t	·	II. *	
indacaterol	Onbrez <i>Breezhaler</i> (75 mcg)	1 inh once a day	\$50	limited coverag
salmeterol	Serevent <i>Diskus</i> (50 mcg)	1 inh BID	\$67	unable to use a LAMA
formoterol	Foradil Aerolizer (12 mcg)	1-2 inh BID (max 48 mcg/day)	\$58 /60 inh	non-benefit COPI
LAMA+LABA Long Acting Musc	arinic Antagonist + Long Acting Beta	2 Agonist	I.	
aclidinium + formoterol	Duaklir <i>Genuair</i> (400/12 mcg)	1 inh BID	\$65	
glycopyrronium + indacaterol	Ultibro <i>Breezhaler</i> (50/110 mcg)	1 inh once a day	\$84	limited coverag
tiotropium + olodaterol	Inspiolto Respimat (2.5/2.5 mcg)	2 inh once a day	\$69	after a 6 month trial of a LAMA or a LABA
umeclidinium + vilanterol	Anoro Ellipta (62.5/25 mcg)	1 inh once a day	\$92	
ICS+LABA Inhaled Corticostero	id + Long Acting Beta ₂ Agonist			
fluticasone propionate + salmeterol	Advair <i>Diskus</i> (250/50 mcg) generics <i>DPI</i> , <i>Inhub</i>	1 inh BID	\$113 \$56 generic	limited coverage
	Advair <i>Diskus</i> (500/50 mcg) generics <i>DPI, Inhub</i>	1 inh BID	\$161 \$78 generic	after a 6 month trial of a LAMA or a LABA & frequent exacerbations
fluticasone furoate + vilanterol	Breo Ellipta (100/25 mcg)	1 inh once a day	\$94	querre exacer butions
budesonide + formoterol	Symbicort <i>Turbuhaler</i> (200/6 mcg)	2 inh BID	\$95	non-benefit
CS+LAMA+LABA Inhaled Cortic	costeroid + Long Acting Muscarinic A	Intagonist + Long Acting Beta ₂ Agonist		
	2 0			limited coverag
fluticasone furoate + umeclidinium + vilanterol	Trelegy Ellipta (100/62.5/25 mcg)	1 inh once a day	\$143	after a 6 month trial of LAMA+LABA or ICS+LAB & frequent exacerbation

¹ Health Canada Drug Product Monographs; ² BC PAD COPD Newsletter 2017